Evaluate the Long Term Safety and Efficacy of DWP16001 add-on to Metformin in Patients With T2DM Inadequately Controlled on Metformin (ENHANCE-MEXT)
Primary Purpose
T2DM (Type 2 Diabetes Mellitus)
Status
Completed
Phase
Phase 3
Locations
Korea, Republic of
Study Type
Interventional
Intervention
DWP16001
Sponsored by

About this trial
This is an interventional treatment trial for T2DM (Type 2 Diabetes Mellitus)
Eligibility Criteria
Inclusion Criteria:
- Participated in the prior phase 3 study (Protocol No: DW_DWP16001302) for meeting the inclusion criteria and completed the study
- Voluntarily decided to participate in the extension study and provided a written consent on the consent form
Exclusion Criteria:
- Withdrawn from the prior phase 3 study (Protocol No: DW_DWP16001302) or expected of having safety issue if taking part in the study in the judgment of the investigator
Subjects with the following diseases or signs:
- Diabetic ketoacidosis
- Moderate to severe renal impairment (estimated glomerular filtration rate [eGFR] < 60 mL/min/1.73 m2
- Females who are pregnant or breast-feeding, or subjects who do not agree to the use of appropriate contraceptive methods throughout the study
Subjects must agree to one of the following appropriate contraceptive methods for subjects or their partners:
① Either surgical sterilization (vasectomy, etc.) or insertion of an intrauterine device (copper loop, intrauterine hormone-containing system), or
② A physical barrier method combined with either systemic hormonal contraceptives or spermicide, or
③ Use of male condom combined with either cervical cap or diaphragm Determined to be ineligible for the study by the investigator, besides the above
Sites / Locations
- Daewoong pharmatceutical
Arms of the Study
Arm 1
Arm Type
Experimental
Arm Label
DWP16001 Amg
Arm Description
DWP16001 Amg, Tablets, Orally, Once daily
Outcomes
Primary Outcome Measures
Changes from baseline in Adverse events (AEs) and adverse events of special interest (AESIs)* at Weeks 6, 12, 18, 24, 38, and 52 after administration of the IP
*Hypoglycemia, urinary tract infection, genital infection, pollakiuria, or polyuria
Secondary Outcome Measures
Changes from baseline* in HbA1c at Weeks 6, 12, 18, 24, 38, and 52 after administration of the IP
* Visit 2 (randomization) of the prior phase 3 study (Protocol No: DW_DWP16001302)
Changes from baseline* in FPG at Weeks 6, 12, 18, 24, 38, and 52 after administration of the IP
* Visit 2 (randomization) of the prior phase 3 study (Protocol No: DW_DWP16001302)
Proportion of subjects achieving HbA1c target of < 7% at Weeks 6, 12, 18, 24, 38, and 52 after administration of the IP
* Visit 2 (randomization) of the prior phase 3 study (Protocol No: DW_DWP16001302)
Full Information
NCT ID
NCT05376969
First Posted
January 9, 2022
Last Updated
October 23, 2022
Sponsor
Daewoong Pharmaceutical Co. LTD.
1. Study Identification
Unique Protocol Identification Number
NCT05376969
Brief Title
Evaluate the Long Term Safety and Efficacy of DWP16001 add-on to Metformin in Patients With T2DM Inadequately Controlled on Metformin
Acronym
ENHANCE-MEXT
Official Title
A Multi-center, Open-label, Extension Study to Evaluate the Long Term Safety and Efficacy of DWP16001 add-on to Metformin in Patients With Type 2 Diabetes Mellitus Inadequately Controlled on Metformin
Study Type
Interventional
2. Study Status
Record Verification Date
October 2022
Overall Recruitment Status
Completed
Study Start Date
May 25, 2021 (Actual)
Primary Completion Date
May 16, 2022 (Actual)
Study Completion Date
May 16, 2022 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Daewoong Pharmaceutical Co. LTD.
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
5. Study Description
Brief Summary
A Multi-center, Open-label, Extension study to Evaluate the long term Safety and Efficacy of DWP16001 add-on to metformin in Patients with type 2 diabetes mellitus inadequately controlled on metformin
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
T2DM (Type 2 Diabetes Mellitus)
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
159 (Actual)
8. Arms, Groups, and Interventions
Arm Title
DWP16001 Amg
Arm Type
Experimental
Arm Description
DWP16001 Amg, Tablets, Orally, Once daily
Intervention Type
Drug
Intervention Name(s)
DWP16001
Intervention Description
DWP16001 Tablets
Primary Outcome Measure Information:
Title
Changes from baseline in Adverse events (AEs) and adverse events of special interest (AESIs)* at Weeks 6, 12, 18, 24, 38, and 52 after administration of the IP
Description
*Hypoglycemia, urinary tract infection, genital infection, pollakiuria, or polyuria
Time Frame
at Weeks 6, 12, 18, 24, 38, and 52 after administration of the IP
Secondary Outcome Measure Information:
Title
Changes from baseline* in HbA1c at Weeks 6, 12, 18, 24, 38, and 52 after administration of the IP
Description
* Visit 2 (randomization) of the prior phase 3 study (Protocol No: DW_DWP16001302)
Time Frame
at Weeks 6, 12, 18, 24, 38, and 52 after administration of the IP
Title
Changes from baseline* in FPG at Weeks 6, 12, 18, 24, 38, and 52 after administration of the IP
Description
* Visit 2 (randomization) of the prior phase 3 study (Protocol No: DW_DWP16001302)
Time Frame
at Weeks 6, 12, 18, 24, 38, and 52 after administration of the IP
Title
Proportion of subjects achieving HbA1c target of < 7% at Weeks 6, 12, 18, 24, 38, and 52 after administration of the IP
Description
* Visit 2 (randomization) of the prior phase 3 study (Protocol No: DW_DWP16001302)
Time Frame
at Weeks 6, 12, 18, 24, 38, and 52 after administration of the IP
10. Eligibility
Sex
All
Minimum Age & Unit of Time
19 Years
Maximum Age & Unit of Time
80 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Participated in the prior phase 3 study (Protocol No: DW_DWP16001302) for meeting the inclusion criteria and completed the study
Voluntarily decided to participate in the extension study and provided a written consent on the consent form
Exclusion Criteria:
Withdrawn from the prior phase 3 study (Protocol No: DW_DWP16001302) or expected of having safety issue if taking part in the study in the judgment of the investigator
Subjects with the following diseases or signs:
Diabetic ketoacidosis
Moderate to severe renal impairment (estimated glomerular filtration rate [eGFR] < 60 mL/min/1.73 m2
Females who are pregnant or breast-feeding, or subjects who do not agree to the use of appropriate contraceptive methods throughout the study
Subjects must agree to one of the following appropriate contraceptive methods for subjects or their partners:
① Either surgical sterilization (vasectomy, etc.) or insertion of an intrauterine device (copper loop, intrauterine hormone-containing system), or
② A physical barrier method combined with either systemic hormonal contraceptives or spermicide, or
③ Use of male condom combined with either cervical cap or diaphragm Determined to be ineligible for the study by the investigator, besides the above
Facility Information:
Facility Name
Daewoong pharmatceutical
City
Seoul
Country
Korea, Republic of
12. IPD Sharing Statement
Learn more about this trial
Evaluate the Long Term Safety and Efficacy of DWP16001 add-on to Metformin in Patients With T2DM Inadequately Controlled on Metformin
We'll reach out to this number within 24 hrs